Blueprint Medicines Corporation ( BPMC) Stock. Should you Buy or Sell? $ 76.07
-1.63 (-2.19 %)
Blueprint Medicines Corporation AnalysisUpdated on 10-09-2022
|Volume Avg.||$931.91 thousand|
|Market Cap||$4.54 B|
|52 Week Range||$43.46 - $117.86|
Blueprint Medicines Corporation opened the day at $76.07 which is -2.19 % on yesterday's close. Blueprint Medicines Corporation has a 52 week high of $117.86 and 52 week low of $43.46, which is a difference of $74.4. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $4.54 B and total net profit is $180080000 which means the company is trading at 25.23 times profit to market capitalization. Theoretically, if you were to buy Blueprint Medicines Corporation for $4.54 B, it would take 15 years to get your money back. Blueprint Medicines Corporation are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Blueprint Medicines Corporation Stock Forecast - Is Blueprint Medicines Corporation a Buy or Sell?
|DCF Score||Strong Buy|
|PE Score||Strong Sell|
|PB Score||Strong Buy|
Growth and Value
|Net Profit Margin||-3.044|
Valuing Blueprint Medicines Corporation
|Price Book Value Ratio||6.065||Price To Book Ratio||6.065|
|Price To Sales Ratio||19.676||Price Earnings Ratio||-6.464|
How liquid is Blueprint Medicines Corporation
|Debt Ratio||0.373||Debt Equity Ratio||0.595|
|Long Term Debt To Capitalization||0.116||Total Debt To Capitalization||0.126|
Latest news about Blueprint Medicines Corporation
Blueprint Medicines (BPMC) posts top-line data from part 2 of the PIONEER study evaluating Ayvakit in patients with non-advanced systemic mastocytosis. Shares down.
Blueprint unveiled the "long-awaited" results of its study in indolent systemic mastocytosis on Wednesday, and the biotech stock crashed. The post Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results Disappoint appeared first on Investor's Business Daily.
Shares of Blueprint Medicines Corp. BPMC, -2.00% tumbled 11.7% in premarket trading on Tuesday after the company said a Phase 2 clinical trial evaluating Ayvakit in patients with non-advanced systemic mastocytosis, a rare disorder, met the primary and secondary endpoints. However, one Wall Street analyst said he is concerned about the change in the symptom score in the Phase 2 study, compared with the Phase 1 trial.
Blueprint Medicines' (BPMC) earnings and revenues fall shy of estimates for the second quarter of 2022. However, the stock is up.
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - MD, Chief Medical Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Conference Call Participants Ernie Rodriguez - Cowen and Company Dane Leone - Raymond James Andrea Tan - Goldman Sachs Peter Lawson - Barclays Reni Benjamin - JMP Securities Eun Yang - Jefferies Brad Canino - Stifel David Nierengarten - Wedbush Securities Paul Jeng - Guggenheim Securities David Lebowitz - Citi Joel Beatty - Baird Matthew Biegler - Oppenheimer Operator Good morning. My name is Charlie, and I'll be your conference operator today.
About Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.